Immunosuppressive treatment strategies in low-risk MDS

Ganser, Arnold; Passweg, Jakob; Stadler, Michael; Dobbelstein, Christiane; Weissinger, Eva M.

doi:10.1016/j.ctrv.2007.07.003

Cited by 3 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From a study of 1049 adult MDS patients over an 11-year period from 1995-2006, Yue et al [7] provided data supporting previous allegations that hypocellular MDS represents a distinct clinicopathological process [7][8][9][10][11][12][13][14]. From this large series of patients, bone marrow cellularity was based on age-adjusted criteria with hypocellularity less than 30% in patients under 70 years and less than 20% in patients over 70 years.…”

Section: Epidemiologymentioning

confidence: 80%

Advancements in the molecular pathogenesis of myelodysplastic syndrome

Epling-Burnette

List²

2009

Current Opinion in Hematology

View full text Add to dashboard Cite

show abstract

Section: Epidemiologymentioning

confidence: 80%

Advancements in the molecular pathogenesis of myelodysplastic syndrome

Epling-Burnette

List²

2009

Current Opinion in Hematology

View full text Add to dashboard Cite

show abstract

“…Lenalidomide displays superior efficacy in the 5q-syndrome, but low efficacy in other patients with low-risk MDS (34). Additional clinical trials are required to define the potential of immunosuppressive and modulatory treatment in MDS (35,36). Thus, identifying safer and more effective anti-MDS strategies remains a major global health challenge.…”

Section: Discussionmentioning

confidence: 99%

Combination of HDE and BIIB021 efficiently inhibits cell proliferation and induces apoptosis via downregulating hTERT in myelodysplastic syndromes

et al. 2021

View full text Add to dashboard Cite

Treatment for higher-risk patients with myelodysplastic syndrome (MDS) should aim to modify the disease course by avoiding progression to acute myeloid leukemia and improving survival. When a patient is not eligible for intensive chemotherapy and lacks a donor hematopoietic cell source, or for a patient in a poor economic situation, consideration can be given to the use of Chinese herbal medicine. Numerous plant extracts, such as camptothecin, vinblastine and paclitaxel, have been reported to display antitumor effects, serving as potential therapeutic strategies for cancer. In the present study, the ultra-performance liquid chromatography-tandem mass spectrometry system (Waters Corporation) was used to detect the main chemical components of HDE, CCK-8 assay to detect the effects of HDE and BIIB021 on the proliferation of SKM-1 cells; and designed hTERT-small interfering (si) RNAs to detect the effects of HDE and BIIB021 on SKM-1 cell apoptosis after HTERT gene knockdown. The present study investigated a newly extracted coumarin HDE, the active component in Oldenlandia diffusa Willd, which efficiently inhibited SKM-1 (MDS cell line) proliferation and induced apoptosis, as determined by performing Cell Counting Kit-8 and flow cytometry assays, respectively. The effect of HDE was associated with decreased telomerase activity. Moreover, heat shock protein 90 inhibitor BIIB021 significantly enhanced the antitumor effects of HDE on SKM-1 cells. In addition, SKM-1 cell apoptosis was increased in human telomerase reverse transcriptase (hTERT)-knockdown cells compared with the negative control group. Cell apoptosis in hTERT-knockdown SKM-1 cells was further enhanced following HDE, BIIB021 or combination treatment, as evidenced by increased levels of cleaved caspase 3, cleaved caspase 8 and cleaved poly ADP ribose polymerase. Collectively, the results indicated synergistic antitumor effects of HDE and BIIB021, providing a novel therapeutic combination for higher-risk MDS.

show abstract

“…High-risk MDS in young patients is treated with bone marrow transplantation, and trials of aggressive chemotherapy are ongoing. Immunomodulatory therapy aimed at the reversal of suppression of hematopoiesis has been used successfully in early stage disease (9,10).…”

mentioning

confidence: 99%